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1. Introduction 
Gliomas are the most common brain tumor in the central nervous system (CNS). The 
majority of malignant gliomas arise from neoplastic transformation of resident astrocytes. 
Gliomas are very aggressive tumors since they are characterized by widespread invasion of 
brain tissue. The exact pathogenesis and underlying mechanisms for glioma cell infiltration 
are currently unclear. Cell-cell interaction and tissue microenvironment play an important 
role in tumor progression leading to modification and infiltration of surrounding tissue. The 
hypoxic microenvironment contributes to abnormal neovascularization of the glioma.  
Uncontrolled cellular proliferation, abnormal angiogenesis and invasion of surrounding 
tissue make these tumors difficult to treat. Poor prognosis and ineffective treatments for 
glioma point to the necessity of developing new therapeutic strategies.  The use of gene 
therapy to deliver a therapeutic gene may successfully overcome the failure of conventional 
therapies. Although non-cell specific and unregulated promoters have been used to target 
gliomas, it is possible that unregulated vectors elicit damage in cells that do not require the 
therapeutic protein. Thus it may be of value to design a regulated, tissue-specific vector to 
express a therapeutic protein in a specific cell type and to regulate it according to the local 
tissue environment.  
The hypoxic microenvironment is known to play a major role in several conditions 
including cerebral ischemia, retinal angiogenesis, gliomas, and other cancers. Hypoxia 
inducible factor 1 alpha (HIF-1┙), the most common transcription factor induced during 
hypoxia, binds to a hypoxia regulated enhancer (HRE) region of oxygen sensitive genes 
leading to their transcription. By taking advantage of hypoxia for regulating foreign gene 
expression, a hypoxia regulated vector could be exploited to modify the cells that reside 
within the target tissue. Use of a cell-specific promoter would be an added advantage to 
restrict gene expression only in certain cells.  
Our recently developed vector platform works in a manner such that in an hypoxic 
environment, HIF-1┙ will bind to the HRE region and express the foreign protein in a cell- 
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specific manner. These vectors were designed to prevent neovascularization in the eye. 
Using a hypoxia regulated, retinal pigment epithelial cell (RPE)-specific promoter, a vector 
was developed which leads to expression of a therapeutic gene only in RPE cells. By driving 
expression of the human endostatin gene, this vector prevented neovascularization in the 
laser induced mouse model of choroidal neovascularization. Another gene therapy vector 
was constructed using the human GFAP promoter along with several hypoxia regulated 
enhancer and silencer elements. Both of these vectors have been tested in different cell lines 
to show specificity and hypoxic-inducibility. The regulated promoter is active only during 
the conditions of hypoxia, and shows significantly enhanced induction of reporter genes, 
especially in primary rat astrocytes in culture. 
Our hypoxia-regulated, astrocyte-specific vector has the capacity to restrict its expression to 
astrocytes and can be expressed only in the hypoxic microenvironment thus remaining 
inactive both under hypoxic and normoxic conditions in other cells. This vector has a unique 
potential for treating pathology in which astrocytes and an hypoxic environment play a 
major role in disease progression. Our goal is to use our regulated astrocyte-specific 
promoter in vectors designed to target gliomas in which both astrocytes and a hypoxic 
microenvironment are involved. Potential therapeutic proteins can be added to the 
downstream region of the promoter to prevent abnormal angiogenesis, induce apoptosis in 
tumor cells and/or prevent invasion and infiltration of the glioma. The following points will 
be discussed in section 2 through 6. 
a. Importance of gene therapy to target gliomas utilizing the hypoxic micro-environment. 
b. Design and testing of hypoxia-regulated astrocyte- specific promoter. 
c. Vector choice and route of delivery. 
d. Therapeutic window for treatment of gliomas. 
e. Future directions and limitations of proposed treatment. 
2.  Importance of gene therapy to target gliomas utilizing the hypoxic micro-
environment 
Gliomas are tumors of the CNS which arise from glial cells.  They are divided into several 
types depending on clinical features and histopathology.  According to the WHO 
classification, gliomas can be classified into fours grades depending upon their 
malignancies: Grade 1 covers benign tumors (e.g. pilocytic astrocytoma), and group II to IV 
are malignant neoplasias which differ in aggressiveness. The most aggressive glioblastoma 
belongs to group IV. Histopathologically, gliomas are divided into astrocytomas, 
oligodendrocytomas and glioblastomas depending upon the type of macroglial cell. The 
most common form of gliomas in humans is the astrocytoma, and the most aggressive form 
of astrocytomas is glioblastoma multiforme (GBM.)  
Gliomas are characterized by their active propagation through nervous tissue. There is a 
limitation of space for glioma growth in the CNS due to existence of firm boundaries (skull 
for the brain and vertebra for the spinal cord). In order to grow, gliomas must clear space by 
actively eliminating the surrounding healthy cells and actively propagate neoplasmic cells 
in the brain parenchyma. Malignant gliomas produce space for expansion by secreting 
increased amounts of excitatory neurotransmitters which kill neighboring neurons. First, 
they express metalloproteinases which assist in breaking down the extracellular matrix and 
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producing migrating channels. Second, glioma cells are able to undergo substantial 
shrinkage, which helps them attain an elongated shape and thus penetrate into narrow 
interstitial compartments.  
Poor prognosis, short survival time and poor response to chemotherapeutic drug 
intervention make glioma a devastating disease. The reason for the poor efficacy of these 
agents includes the selectivity of the blood brain barrier, the heterogeneity and low 
immunogenicity of gliomas and appropriate selection of chemotherapy-resistant clones. 
New therapeutic strategies are therefore needed to treat this devastating tumor. Since 
multiple genes determine the severity of glioma progression and invasion, theoretically the 
design of a therapeutic strategy could be targeted utilizing the tumor microenvironment. A 
major set of therapeutic targets could involve changes in the molecular pathways associated 
with the hypoxic environment. 
2.1 Molecular basis of glioma 
Molecular and genetic approaches have provided dramatic insights into glioma biology. As 
part of the intensive effort to determine the process of glioma formation, several molecular 
defects have been implicated in gliomas. These genes affect encoded proteins involved in 
several critical biologic processes, including signal transduction, cell growth, cell cycle 
control or proliferation, apoptosis and differentiation.  
An hypoxic microenvironment is a frequent characteristic of GBM since these tumors exhibit 
abnormal neovascularization, irregular blood flow, and a high rate of oxygen consumption 
by the rapidly proliferating malignant cells.  Regions of low oxygen concentration are a 
characteristic feature of growing tumors and are frequently found around necrotic areas. 
Hypoxic microenvironments are powerful stimuli for the expression of genes involved in 
tumor cell proliferation, angiogenesis and immuno-suppression. Tumor hypoxia activates a 
complex set of cellular responses which are differentially regulated by two members of 
hypoxia-inducible transcription factors family; hypoxia inducible factors 1 and 2 (HIF-1 and 
HIF-2). It has been shown that HIFs control tumor stem cell phenotype and the acquisition 
or maintenance of stem cell properties (Seidel et al., 2010). 
2.2 Significance of hypoxia in glioma 
Histological studies suggest that gliomas are abnormally vascularized due to highly 
proliferating tumor cells which exhibit slow or inefficient blood flow. Evans et al have 
shown that the physiological oxygen concentration varies between 2.5% to 12.5%  in healthy 
brain tissue. The majority of GBMs examined showed mild to moderate/severe hypoxia 
with oxygen concentration ranging between 0.5% to 2.5% to (pO2 = 20-40mm Hg) for mild 
hypoxia and 0.5%-0.1 % (pO2 0.75mm to 4 mm Hg) for moderate/severe hypoxia (Evans et 
al., 2004a, Evans et al., 2004b, Evans et al., 2008). Although some researchers do not include 
moderate hypoxia as major factor in the pathogensis of glioma, an oxygen tension of 0.5% to 
2.5% would likely be appropriate to model the hypoxic environment since HIF-1 elevation 
occurs in GBM patients (Kaynar et al., 2008). 
There are several cellular responses to hypoxia and all are controlled by the expression of 
different transcription factors which are called hypoxia inducible factors (HIF-1-3α). These 
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transcription factors produce dimerization with HIF-1┚ which is expressed constitutively 
followed by translocation to the nucleus. Under normal conditions, HIF1 ┙ is expressed 
ubiquitously at low levels in all organs. The HIF-1α subunit has an oxygen-dependent 
degradation domain which leads to rapid ubiquination and degradation by the proteasome 
(Figure 1). During hypoxia, the hydroxylation of HIF-1α is inhibited, leading to 
accumulation of HIF-1α protein. The accumulated HIF-1 binds to hypoxia responsive 
regions (HREs) of several genes inducing their transcription. Many of these genes play a 
critical role in important aspects of cancer biology: angiogenesis, cell survival, 
chemotherapy, radiation-resistance, genomic instability, invasion and metastasis, and 
glucose metabolism  (Bar et al., 2010). 
 
Fig. 1. Hypoxia induces the expression of hypoxia inducible factors (HIF-1) which are 
composed of two subunits HIF-1α and HIF-1┚. During normoxia HIF-1α is degraded by the 
proteasomal ubiquitination. In absence of oxygen HIF-1┙ is stabilized by binding with HIF-
1┚ to form HIF-1. The HIF-1 translocates into the nucleus and binds to sequence of hypoxia 
responsiveelement (HRE) of several genes to induce the gene transcription. 
2.3 Hypoxia promotes angiogenesis, glioma cell migration and immunosuppression 
Hypoxia induced HIFs act as a proangiogenic switch to drive angiogenesis in gliomas. HIF 
is expressed inside tumor cells and astrocytes in response to changes in oxygen availability 
of the surrounding tissue. HIF-1 stimulates the expression of the potent angiogenic factor, 
vascular endothelial growth factor (VEGF). VEGF belongs to the family of growth factors 
which include VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and Placental growth factor. 
VEGF-A also exists with different splice variants (VEGF 121, 145, 165, 189 and 206). 
Different cell surface receptors for VEGF are expressed in endothelial cells. VEGF is 
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regarded to be the major factor for development of new vessels both in physiological and 
pathological angiogenesis. VEGFs not only stimulate the proliferation of endothelial cells, 
but they are also responsible for migration, vascular permeability and invasiveness during 
the angiogenic process. Production of high levels of VEGF is reported in cystic fluid and also 
around necrotic tissue in GBM patients (Brat and Van Meir, 2004). 
Other than VEGF, HIF-1 also stimulates the expression of other angiogenic growth factors 
which include placental growth factor, basic fibroblast growth factor (bFGF), early growth 
factor, platelet growth factor Beta (PDGF-┚), angiopoietin-1 (Ang1) and-2 (Ang-2). Along 
with the receptors for vascular proliferation, the endothelial cells express several receptor 
tyrosine kinases like Tie-1 and Tie-2 which regulate vessel remodeling, maturation and 
endothelial survival (Nawroth et al., 1993). Ang-1 facilitates the stabilization of new blood 
vessels and prevents leakiness, whereas in response to availability of VEGF, Ang-2 causes 
vascular remodeling and growth of new blood vessels. In the absence of Ang-2, regression 
of vessels occurs (Holash et al., 1999). The levels of angiopoetins and Tie-2 are greatly 
elevated in GBM samples indicating profuse tumor vascularity and invasiveness (Reiss et 
al., 2005). 
Another potent growth factor, TGF-┚ and its receptor are highly expressed in gliomal 
tissues. These growth factors are activated by several proteases and integrins in the hypoxic 
microenvironment. TGF-beta regulates angiogenesis by activating several growth factors 
and their receptors including bFGF, PDGF, PDGFR, and EGFR. TGF-B affects angiogenesis 
by stimulating tumor cells to secrete VEGF and integrins which facilitates the motility of 
endothelial cells within the glioblastoma tumor.  
Glioma cell migration and invasion depends on HIF-1 induced extracellular matrix 
proteases. Matrix metaloproteases (MMPs) play a major role in extracellular matrix (ECM) 
degradation and facilitate proliferation and migration of endothelial cells to produce new 
blood vessels. MMPs also modulate several growth factors and cytokines which affect the 
endothelial and tumor cell migration ultimately inducing angiogenesis. Lolmede et.al., 2003 
reported that several MMPs, including MMP-1, MMP-1, MMP-7 and MMP-9, are activated 
by HIF-1 dependent pathways (Lolmede et al., 2003). HIF-1 activates TGF-β2, which further 
regulates the activity of MMPs resulting in suppression of tissue inhibitor of 
metalloproteases (TIMPs) (Wick et al., 2001). The level of MMP-1 expression is upregulated 
in several cancers and activates the expression of MMP2 in gliomal cells. Tumor prognosis 
and vascularity are directly related to the expression of MMPs in gliomas. 
Tumor hypoxia can activate the pSTAT3 pathway which triggers the downstream 
expression of HIF-1┙. In gliomas, several immunosuppressive cytokines, including TGF-┚, 
soluble colony stimulating factor-1 (sCSF-1), chemokine ligand 2 (CCL2) and galectin 
expression, are induced by HIF during hypoxia. Macrophages (microglia) are the dominant 
infiltrating cells in gliomas. These macrophages become tumor-associated macrophages 
(TAM) when exposed to the hypoxic tumor microenvironment. The TAMS contribute 
towards tumor angiogenesis and invasion by activating the STAT3 pathway ultimately 
resulting in immuno-suppression and tumor supportive phenotypes. HIF -1 promotes 
expansion of CD133 positive glioma cancer stem cells (gCSCs) which play a role in immuno-
suppression. Up-regulation of expression of macrophage migration inhibitory factor genes 
(MIFs) in glial cells is associated with glioma and promotes tumor angiogenesis and 
immunosuppression (Bacher et al., 2003). 
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2.4 Hypoxia as the therapeutic target 
Since hypoxia modulates the glioma progression and metastasis, it can be targeted to 
minimize hypoxic effects on tumor cells. Several HIF-1 inhibiting agents have been used to 
inhibit the growth and spread of tumor cells (Jensen, 2009). Although activation of HIF-1 
induces tumorgenesis, it is also necessary for normal cellular function including 
physiological angiogenesis, growth and survival. Therefore it is not wise to inhibit the 
activity of HIF-1 completely using anti-HIF agents. Several strategies have been developed 
to express therapeutic proteins under hypoxic conditions under the control of an HRE 
containing promoter (Ruan and Deen, 2001).   
HIF-1 binds to the region of HRE elements and activates gene expression. An expression 
vector using hypoxia inducible cytosine deaminase has been used for cancer in a pro-drug 
activation strategy (Wang et al., 2005). During hypoxia, cytosine deaminase is expressed and 
converts a non-toxic 5-fluorcytosine to the highly toxic chemotherapeutic agent 5-
fluoruracil. Several researchers are using this approach to activate enzymes required for 
apoptosis or tissue protection by the process of pro-drug activation (Binley et al., 1999, Ruan 
et al., 1999, Shibata et al., 2000, Cao et al., 2001). Along with hypoxia regulated expression, 
tissue-specific expression may increase the possibilities to turn on genes in a regulated and 
tissue-specific manner. McKie EA (1998) used a GFAP promoter to target astrocytes for 
expression of transgenes as a potential treatment strategy for glioblastoma (McKie et al., 
1998). Hypoxia could be used to switch on a foreign gene in glioma cells or in astrocytes. We 
have designed an hypoxia-regulated, astrocyte-specific vector which will lead to gene 
expression only in hypoxic astrocytes while restricting expression in normoxia and other cell 
types.  
 
Fig. 2. Construction of hypoxia-regulated astrocyte –specific vector. Three copies of neuron 
restrictive silencer sequence (S) and three copies of hypoxia responsive element (HRE) 
sequence were alternated in a combination to make hypoxia responsive silencer elements 
(HRSE). This sequence provides conditional silencing in normoxia and induces gene 
expression in hypoxia. Similarly 6 copies of HRE sequence were combined together to make 
6XHRE for enhanced hypoxic induction. A ) Sequences of HRSE, 6XHRE and human glial 
fibrillary acidic protein (GFAP) promoter are incorporated into pGL3-basic vector to drive 
luciferase (LUC) gene expression. B) Sequences of HRSE, 6XHRE and human GFAP 
promoter are incorporated into self complementary Adeno Associated Virus plasmid vector 
(scAAV) to make scAAV2 virus which drives the green fluorescent protein (GFP) gene.  
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3. Design and testing of hypoxia-regulated, astrocyte- specific promoter 
Astrocyte specific expression in transgenic mice was shown by Lee et.al. in 2008 (Lee et al., 
2008). Different conserved domains of the GFAP promoter are used to demonstrate 
astrocytic specific reporter gene expression. A promoter domain designated Gfabc1d 
(GFAP) consisting of selected subdomains of the GFAP promoter was shown to exhibit 
region and astrocyte specific transgene expression in the brain of a transgenic rat. Our lab 
developed an hypoxia regulated vector (Dougherty et al., 2008) in which a hypoxia 
responsive enhancer was used together with the retinal pigment epithelial cell (RPE65) 
(Dougherty et al.). This promoter cassette drives cell-specific and hypoxia responsive 
transgene expression in cell culture. It was used successfully to drive transgene expression 
of an anti-angiogenic agent to prevent the neovascularization in the mouse eye following 
laser treatment (personal communication). These positive results lead us to develop another 
cell-specific promoter to drive gene expression in astrocytes during hypoxia. 
 
Fig. 3. Hypoxia responsive luciferase expression controlled by the regulated promoter in 
astrocytes. pGL3-HRSE-6XHRE-Luc plasmid was transfected to rat primary astrocytes. The 
transfected cells were exposed to either 0.5 % hypoxia or normoxia. After 40hrs of hypoxic 
or normoxic exposure, for testing the activity of the promoter, luciferase gene expression 
was measured using Promega’s Dual Glow luciferase assay kit (DLA). The activity of 
regulated promoter showed more than 15-fold induction in hypoxia compared to its 
normoxc counterpart.  
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We have designed astrocyte-specific promoters in a pGL3 based vector containing hypoxia 
responsive elements (HREs), silencer domains and the human GFAP promoter that provide 
both cell specificity and hypoxia inducible expression as well as normoxic silencing. The 
human GFAP promoter in a plasmid vector was a generous gift from Dr. Brenner 
(University of Alabama, Birmingham, AL). The promoter element was amplified and ligated 
to a pGL3 basic vector to drive the luciferase reporter gene.  This construct was named 
pGL3-GFAP-Luc and is referred to as the unregulated plasmid vector. The addition of 6 
copies of the HRE element (Dougherty et al., 2008) will be a target for HIF-1 to bind to and 
hence turn on gene expression during hypoxia. Incorporation of a silencer element (HRSE) 
(Dougherty et al., 2008) to the HRE will prevent the expression of the transgene in normoxia 
and maximize the expression of the transgene in hypoxia. The newly constructed plasmid 
pGL3-HRSE-6XHRE-GFAP-Luc is referred to as regulated plasmid vector (Figure 2A). 
Rat primary astrocytes and other cell lines were transfected with the plasmids using 
lipofectamine. After 40 hours of hypoxic or normoxic exposure, the dual luciferase assay 
was performed to measure the activity of the promoters. Our preliminary results show that 
the GFAP promoter was modestly activated (< 3 fold), whereas the regulated GFAP 
promoter was induced by more than 15-fold in hypoxia and was tissue specific (Figure 3). 
Promoter constructs were incorporated into a self-complementary Adeno Associated Virus 
(scAAV) plasmid vector and produced in large quantities (Figure 2B). Vector specificity and 
hypoxia regulation were tested in cultures of primary rat astrocytes. Our results 
demonstrated that the regulated promoter construct was completely silenced in aerobic 
conditions in cultures of primary astrocyte. Hypoxic-exposure induced high levels of GFP 




A                                                                               B 
Fig. 4. Hypoxia responsive GFP expression from the regulated vector. scAAV2-HRSE-
6XHRE-GFAP-GFP virus vector was transduced tinto primary rat astrocytes (1 X 10^3 viral 
particles per cell). After 3 days of transduction, the cells were exposed to either 0.5% 
hypoxia or normoxia for 6 days.  In normoxia, the transduced astrocytes do not express GFP 
(A) whereas in hypoxia, the transduced astrocytes show high level induction of the 
promoter by expressing GFP (B). 
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4. Vector choice and route of delivery 
Although current therapeutic interventions provide improvements in glioma therapy, these 
treatments do not result in long term cures. Development of gene therapy could be a 
potential strategy for long term treatment of GBM. Glioma is an ideal target for gene 
therapy because, unlike other solid tumors, it rarely metastasizes outside the CNS. Over 30 
clinical trials using gene therapy vectors have been initiated with more than 400 glioma 
patients enrolled worldwide.  
The major requirement of gene therapy is to develop vectors which are safe and efficient to 
deliver the therapeutic genes to a targeted cell type. Several viral and non-viral vectors are 
being used to transfer genes in both experimental models and clinical research applications. 
Although non-viral methods have advantages over the viral methods in terms of their large 
scale production and low host immunogenicity, low levels of transfection and expression of 
the gene limit their use. Mostly viral vectors have been used as vehicles to carry exogenous 
genes into human cells since they bind to the host cell and introduce genetic material into 
the cytoplasm or nucleus as a part of their replication cycle. Viruses used in glioma gene 
therapy generally fall into two categories: replication incompetent viruses (from which all or 
most of its genome has been removed) and replication competent viruses (where select viral 
genes are deleted or mutated so that viruses can replicate and lyse tumor cells selectively) to 
minimize toxicity and retain gene delivery efficiency (Iwami et al., 2010). Adenoviruses 
(AdV) or retrovirus (RVs) have both been used in clinical trials to treat gliomas.  
Expression of a therapeutic protein depends on choice of vector and the route of delivery. 
There are several possible routes of delivery including systemic administration, stereotactic 
injection, intratumoral injection, intramuscular injection, and facial vein injection.   
Liposomal delivery of HSV-tk has been used to target gliomas using cationic liposomes 
carrying the human interferon beta gene (Yoshida et al., 2004) in a clinical trial. Adeno viral 
mediated HSV TK along with the pro-drug ganciclovier was used to treat human glioma 
(Immonen et al., 2004). Lenti-viral mediated transfer of GAS1 (Lopez-Ornelas et al., 2011) to 
human gliomas has been used to arrest cell proliferation, cause apoptosis and inhibit tumor 
growth. A combinational therapy using baculovirus-mediated expression of p53 along with 
sodium butyrate was also tested to treat human glioblastoma (Guo et al., 2011). AAV is one 
of the preferred vectors for gene therapy since it is less immunogenic and has an increased 
rate of transduction efficiency. Research using a variety of serotypes or mutations in the 
vector capsids has led to better vectors to target specific cell types for expression of the 
therapeutic protein. It may be preferable to produce a regulated or modest amount of 
transgene expression (McCarty et al., 2003) in a greater number of cells rather than 
overproduction in a small number of cells. 
Despite its limited capacity in harboring larger size genes, development of the scAAV 
genome advances AAV gene therapy due to increased transduction efficiency. The scAAV 
genome is proven to be very suitable  for both dividing and non-dividing cells in transgenic 
mice (Choi et al., 2006). The scAAV has also been used to target both neurons and glia using 
either intrathalamic or intraventricular injection (Chen et al., 1998, Chen et al., 1999). AAV 
mediated HSV-tk was targeted in mice bearing human glioma in conjunction with 
ganciclovir administration (Mizuno et al., 1998). Intramuscular injection of AAV has been 
used to deliver angiostatin to suppress glioma growth in nude mice (Ma et al., 2002). 
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Similarly AAV-8 was used to deliver soluble VEGF receptor to the CNS to trap the VEGF in 
orthotopic brain tumor models of GBM (Harding et al., 2006). 
AAV mediated expression of the c-terminal fragment of the human telomerase reverse 
transcriptase gene (hTERTC27) has proven to be highly effective to reduce tumor growth in 
human glioblastoma xenografts mouse model (Ng et al., 2007). A chimeric AAV capsid was 
developed to enhance glioma cell transduction (Maguire et al., 2010). Stereotaxic injections 
of different AAV serotypes into the striatum of rat brain are reported to enhance glial 
delivery of the therapeutic protein. Intravenous or intracisternal injection of scAAV2 vectors 
have been used to study global distribution and dispersion of AAV in a mouse brain (Fu et 
al., 2003). Although several serotypes of AAV were used, it has been reported that AAV5 
and AAV9 appears to best for enhanced glial transduction (Foust et al., 2009, Markakis et al., 
2010). 
5. Gene therapy strategies for glioma 
An extensive range of genes and their signaling pathways contribute to glioma development 
and the level of severity. It may not be appropriate to consider only one gene or factor for 
prevention of glioma in a therapeutic strategy. Combinational therapy and pro-drug 
activation are now being used along with chemotherapy and radiation therapy. The most 
effective gene therapy strategy in use both in experimental and clinical gene therapy trials 
employs HSV-tk. While it may prevent the tumor growth initially, HSV-tk cannot reduce 
glioma growth at a later stage due to its dependence for cell killing on gap junctions 
between tumor cells. Ultimately a more effective strategy for cell killing may involve 
developing vectors which can target the local tumor environment.   
5.1 Use of cytotoxic or suicidal approach  
The suicidal gene therapy approach has been the most generally used in gene therapy 
clinical trials for glioma. The HSV-tk method which requires a pro-drug to elicit its effect is 
extensively employed for this purpose. HSV-tk enhances the sensitivity of transduced tumor 
cells towards the non toxic pro-drug ganciclovir, acyclovir or valaciclovier and then 
metabolizes the pro-drug into a cytotoxic agent which acts as a potent inhibitor of DNA 
replication (Tiberghien, 1994, Tiberghien et al., 1994). Several vectors have been used to 
drive expression of HSV-tk for killing of tumor cells. The effectiveness of suicidal gene 
therapy mediated by HRE cre/lox driving HSV-tk has been evaluated in a model of tumor 
xenografts implanted in nude mice (Greco et al., 2006). In a similar strategy a hypoxia 
regulated expression vector was used to drive the expression of cytosine deaminase gene 
which activates another pro-drug 5-fluorocytosine to form the highly toxic 5-fluoruracil 
(Chen et al., 2005, Wang et al., 2005). This cytotoxic compound was able to significantly kill 
glioblastoma cells in a hypoxia-dependent manner while exerting no toxicity on normal 
cells. Hypoxia regulated carboxyl esterase expression has been generated  using an adeno 
viral based  gene expression system, resulting in conversion of a pro-drug Irinotecan (CPT-
11) to its active cytotoxic metabolite which is capable of killing glioma cells (Matzow et al., 
2007). Based upon the above evidence of the feasibility of employing hypoxia regulated gene 
expression in a suicide gene therapy strategy, our vector may be highly applicable for 
delivering therapeutic genes in astrocytes for control over tumor growth.  
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5.2 Gene targets involving cell cycle arrest and apoptosis  
Transfer of cell cycle genes could be a good strategy for blocking glioma growth (Fueyo et 
al., 2001). The E2F family of transcription factors contributes to the regulation of cell cycle 
and cell death genes in glioma. It has been shown that over expression of E2F-1 enhances the 
anti-glioma effect through increasing apoptosis in human glioma cells (Mitlianga et al., 
2002). Another important strategy may be to induce cell cycle arrest and prevent the 
proliferation of the tumor cells. Soluble form of Gas1 protein is being used by lenti-viral 
gene transfer methods to arrest the cell cycle (Lopez-Ornelas et al., 2011), (Zamorano et al., 
2003), (Zamorano et al., 2004) and preventing the proliferation of glioma cells in nude mice. 
Hypoxia regulated expression of these proteins has been proposed as a viable approach that 
can be applied to tumor killing. 
The tumor cytokines TNF alpha and IFN beta are very good candidates for inducing 
apoptosis in hypoxic glioma cells when the respective genes are incorporated into our 
hypoxia regulated vector. The secretable form of trimeric Tumor Necrosis Factor-Related 
Apoptosis-Inducing Ligand (TRAIL) has been employed for to targeting gliomas and 
inducing apoptosis in glioblastoma (Jeong et al., 2009) and TRAIL therefore is also an 
excellent candidate for incorporation into a regulated gene therapy vector. Overexpression 
of bone morphogenetic protein (BMP4) was employed  to induce apoptosis in glioma stem 
cells (Zhou et al., 2011) and therefore BMP4 represents a good candidate for enhancing 
tumor killing.  Numerous studies have demonstrated detailed mechanisms by which BMP4 
acts to induce BAX and inhibit BCl2 as well as Bcl-X family members.  Glioma cells exhibit 
low endoplasmic reticulum (ER) stress. It is possible that over-expression of ER stress factors 
could be effective for inducing apoptosis in glioma. ER stress induces C/EBP homologous 
protein (CHOP) which is a key regulator for cellular apoptosis (Eom et al., 2010). Regulated 
expression of CHOP would also be valid for inducing apoptosis in tumor cells (Kim et al., 
2011).  
Gliomas can be targeted by overexpression of micro RNAs (miR). It has been demonstrated 
that miRs also play an important role in regulation of oncogenes and/or tumor suppressor 
genes at the post-transcriptional and/or translational level. Oligonucleotides mimicking 
miR-451 are used to inhibit cell growth, induce G0/G1 phase arrest and enhance apoptosis 
in different glioma cell lines. Targeting miR-451 also decreases the expression levels of Akt1, 
CyclinD1, MMP-2, MMP-9 and Bcl-2 genes while increasing expression of the tumor 
suppressor genes p27 in dose dependent manner (Nan et al., 2010). Adenoviral mediated co-
expression of shRNAs for miR-221 and 221 have been used to induce apoptosis in tumor 
cells (Wang et al., 2011). Mir-34a was overexpressed in a p53 mutant glioma cell line with 
resulting induction of   apoptosis.  
Inhibition of MMPs may be a valuable strategy for suppressing glioma growth in regulated 
manner through induction of apoptosis. In a previous study siRNA mediated 
downregulation of urokinase-type plasminogen activator receptor (uPAR) and matrix 
metalloproteinase-9 (MMP-9) were employed to activate caspase-9 mediated apoptosis in 
glioma (Gondi et al., 2008). It is reported that miR-21 is involved in regulation of genes for 
glioma cell proliferation, migration and invasion through activation of several MMPs. 
Downregulation of miR-21 may  be an effective strategy for blocking the expression of 




Novel Therapeutic Concepts in Targeting Glioma 210 
5.3 Anti angiogenic approach 
Tumor hypoxia is implicated as a major stimulus for the growth of new blood vessels in 
tumor angiogenesis through inducing expression of most potent angiogenic factor VEGF. 
Tumor angiogenesis facilitates the invasion of tumor cells into normal tissue. Inhibiting pro-
angiogenic factors such as VEGF, targeting VEGF receptors and over expressing 
endogenous anti angiogenic factors holds promise as a good strategy to prevent tumor 
angiogenesis. Since HIF-1┙ mediates increased tumor aggressiveness in hypoxia, direct 
inhibition of HIF-1┙ with siRNA may be effectively used to suppress glioma cell growth and 
reduce tumor invasiveness in a glioma model (Fujiwara et al., 2007). Targeting of VEGF 
signaling pathways and their receptors would provide an efficient treatment for glioma 
angiogenesis. Regulated expression of endogenous anti angiogenic factors (endostatin, 
angiostatin, pigment epithelial derived factor (PEDF), thrombospondin-1) could be 
beneficial in conjunction with other chemotherapeutic agents. Intra-arterial delivery of 
plasmids carrying the endostatin gene results in an 80% reduction in tumor volume, a 40% 
decrease in tumor angiogenesis and increases the survival time of up to 47% in a rat model 
of solitary intracerebral 9L tumors (Barnett et al., 2004). Co-delivery of a angiostatin-
endostatin fusion gene and soluble VEGF receptor (sFLT-1) by a sleeping beauty transposon 
completely inhibited tumor growth and enhanced the survival of animals in an 
experimental GBM model (Ohlfest et al., 2005). AAV mediated delivery of angiostatin was 
used to treat the malignant brain tumor in a C6 glioma/Wistar rat model with a resulting 
inhibition of tumor growth and enhanced time of animal survival (Ma et al., 2002). 
Antisense TGF-beta and soluble VEGF receptors have been exploited to reduce glioma 
gowth (Harding et al., 2006). Overall it has been seen that glioma can evade anti angiogenic 
therapy by up-regulating alternative signaling pathways such as the ILK-1 pathway 
(Verpelli et al., 2010). Targeting both TGF-beta and VEGF pathways simultaneously shows 
promise for an improved treatment strategy. Over-expression of PEDF could also be 
exploited using our regulated vector and in this case the likely results would include 
activities that are neuroprotective and anti-angiogenic (Zhang et al., 2007). Over expression 
of PEDF has recently been shown to inhibit tumor malignancy in a rodent glioma model 
(Guan et al., 2004).  
6. Future directions for development of hypoxia regulated anti glioma 
treatment 
Gene therapy strategies have been broadly applied to treat all forms of glioma. Although 
expression of suicidal genes in tumor cells is effective to a degree in clinical trials, there is a 
risk that the suicidal genes can express in normal cells with detrimental effects. Use of cell 
type specific or cancer cell specific promoters may have advantages over universal 
promoters by restricting gene expression to the desired cells without damaging other cells 
collaterally. The use of vectors driving hypoxia-regulated astrocyte-specific expression of 
genes could be an effective strategy to target tumor cell apoptosis, cell cycle arrest and 
inhibition of key regulators for tumor angiogenesis.   
One of the advantages of a hypoxia regulated promoter is it can restrict the expression of 
genes to hypoxic astrocytes within and in close proximity to  the tumor core while avoiding 
production of the therapeutic protein in neighboring normal cells which may occur when  
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universal promoters are employed.  Until now, surgical removal of tumor tissue in 
combination with radiotherapy has been a relatively effective strategy for treating glioma. 
However one of the major problems is the recurrence of the tumor which is associated with 
ROS induced HIF-1 expression. Upon recurrence of glioma the enhanced HIF-1 levels 
desensitize glioma cells to further treatment.  The regulated vector could be employed to 
resensitize the tumor cells to be more responsive to chemotherapy. Some oncogenes induce 
HIF-1 in tumor cells in the absence of hypoxia (Lim et al., 2004). Our vector can be used to 
respond to HIF expression specifically in glial cells should HIF-1 be activated by any of the 
oncogenes.  
 
As a combinational therapeutic strategy our hypoxia regulated promoter could be employed 
for expressing therapeutic genes encoding an anti-angiogenic factor in addition to a tumor 
suppressor gene. The scope and applications of our hypoxia –regulated gene therapy are 
shown in figure 5. Our strategy of hypoxia-regulated gene therapy may obviate the need for 
radiation therapy and chemotherapy and may be beneficial in terms of preventing tumor 
growth as well as eradication of residual cancer cells in instances where a glioma is removed 
surgically.  
Chapter summary  
• The hypoxic microenvironment is known to play a major role in several diseases 
including age related macular degeneration, cardiac and cerebral ischemia, 
glioma, and other cancers.  
• Many endogenous genes that are induced during hypoxia are activated by the 
binding of the transcription factor HIF-1┙ to a hypoxia regulated enhancer (HRE) 
region in their promoter domain.  
• For effective gene therapy, there is a great need for a vector that can be regulated 
according to the local tissue microenvironment. 
• By taking advantage of hypoxia for regulating foreign gene expression, a hypoxia 
regulated vector including hypoxia regulated enhancer could be exploited to 
modify the cells that reside within the target tissue.  
• Gliomas are the most common brain tumors in the central nervous system and 
the majority of malignant gliomas arise from neoplastic transformation of 
resident astrocytes.  
• Our hypoxia-regulated, astrocyte-specific vector has the capacity to restrict its 
expression to astrocytes and can be expressed only in the hypoxic 
microenvironment thus remaining inactive both under hypoxic and normoxic 
conditions in other cells.  
• A variety of therapeutic gene products could be delivered by our hypoxia-
regulated promoter to prevent abnormal angiogenesis and induce apoptosis in 
tumor cells leading to prevention of invasion and infiltration of the glioma into 
surrounding tissue. 
• One of the major problems in surgical removal of tumor tissue is the recurrence 
of glioma and the enhanced HIF-1 levels desensitize glioma cells to further 
treatment.  The regulated vector could be employed to resensitize the tumor cells 
to be more responsive to chemotherapy. 
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Fig. 5. Strategy for hypoxia-regulated astrocyte-specific gene therapy to treat glioma. The 
regulated-promoter can  be applied to drive expression of genes responsible for tumor 
suppressor, cell cycle arrest, pro-apoptotic and inhibition of pro-angiogenic processes in 
astrocytes . The plasmid vectors can be packaged into either viral (Adeno, Retro and AAV) 
vectors or non-viral liposomes or nano-particles as a potential glioma treatment strategy.  
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